- Home
- WU vs NUVB Comparison
WU vs NUVB Comparison
Compare WU & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WU | NUVB |
|---|---|---|
| Founded | 1851 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | WU | NUVB |
|---|---|---|
| Price | $7.61 | $6.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $9.00 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 7.1M | 6.6M |
| Earning Date | 04-24-2026 | 05-04-2026 |
| Dividend Yield | ★ 10.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $4,050,700,000.00 | N/A |
| Revenue This Year | $8.50 | $203.82 |
| Revenue Next Year | $4.73 | $58.18 |
| P/E Ratio | $40.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.91 | $2.18 |
| 52 Week High | $10.35 | $9.75 |
Technical Indicators
Market Signals| Indicator | WU | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 64.00 |
| Support Level | $8.05 | $5.28 |
| Resistance Level | $8.14 | $6.60 |
| Average True Range (ATR) | 0.30 | 0.37 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 27.73 | 85.91 |
Price Performance
Historical ComparisonAbout WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2025 and is the largest money transfer company in the world.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.